{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:00:42Z","timestamp":1790470842774,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012380","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T00:00:00Z","timestamp":1499040000000}}],"reference-count":132,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012380.pub2","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T15:52:11Z","timestamp":1499097131000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interventions for chronic kidney disease in people with sickle cell disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"Noemi BA","family":"Roy","sequence":"first","affiliation":[{"name":"University of Oxford; Weatherall Institute of Molecular Medicine; John Radcliffe Hospital Headley Way Oxford UK OX3 9DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M","family":"Fortin","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; John Radcliffe Hospital Oxford UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R","family":"Bull","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals Trust and the University of Oxford; Oxford Kidney Unit and Nuffield Department of Medicine; Cornall Group, Henry Wellcome Building for Molecular Physiology Roosevelt Drive Oxford UK OX3 7BN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Systematic Review Initiative; John Radcliffe Hospital Oxford UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialena","family":"Trivella","sequence":"additional","affiliation":[{"name":"University of Oxford; Centre for Statistics in Medicine; Botnar Research Centre Windmill Road Oxford UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hopewell","sequence":"additional","affiliation":[{"name":"University of Oxford; Oxford Clinical Trials Research Unit; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences Windmill Road Oxford Oxfordshire UK OX3 7LD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"NHS Blood and Transplant; Haematology\/Transfusion Medicine; Level 2, John Radcliffe Hospital Headington Oxford UK OX3 9BQ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,7,3]]},"reference":[{"key":"10.1002\/14651858.CD012380.pub2-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Adams RJ Barredo J Bonds DR Brown C Casella J Daner L TCD in infants: A report from the BABY HUG trial Blood 2005","DOI":"10.1182\/blood.V106.11.952.952"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0002|cit2","unstructured":"Adams RJ Luden J Miller S Wang W Rees R Li D TCD in infants: a report from the Baby Hug study 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio. 2005 105"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.24100","article-title":"Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia","volume":"59","author":"Alvarez","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1542\/peds.2012-0283","article-title":"Developmental function in toddlers with sickle cell anemia","volume":"131","author":"Armstrong","year":"2013","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Armstrong FD Elkin TD Brown RC Glass P Rees RC Wang WC Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial Blood 2008","DOI":"10.1182\/blood.V112.11.713.713"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0006|cit6","unstructured":"Armstrong FD Rees RC Li D Bonner M Elkin D Strouse JJ Baseline developmental function by age for children in the pediatric hydroxyurea phase 3 clinical trial (Baby Hug) 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio 2005 137"},{"issue":"3","key":"10.1002\/14651858.CD012380.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clinbiochem.2012.10.032","article-title":"Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial","volume":"46","author":"Kalpatthi","year":"2013","journal-title":"Clinical Biochemistry"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0008|cit8","unstructured":"Lebensburger JD Miller ST Howard TH Casella JF Brown RC Lu M Influence of hemoglobin level on clinical findings in infants with sickle cell anemia; data from BABY HUG 52nd ASH Meeting and Exposition; 2010 Dec 4-7; Orlando, Florida 2010"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/pbc.24037","article-title":"Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study","volume":"59","author":"Lebensburger","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1542\/peds.2014-0571","article-title":"Immunologic effects of hydroxyurea in sickle cell anemia","volume":"134","author":"Lederman","year":"2014","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Lederman HM Connolly MA Ware RE Luchtman-Jones L Goldsmith JC Effects of hydroxyurea (HU) on lymphocyte subsets and the immune response to pneumococcal, measles, mumps and rubella vaccination in the pediatric hydroxyurea phase III clinical trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400) Blood 2012","DOI":"10.1182\/blood.V120.21.243.243"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ebm.2011.100104","article-title":"Hydroxycarbamide for very young children with sickle cell anaemia: No effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity","volume":"17","author":"Manwani","year":"2012","journal-title":"Evidence-based Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012380.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2214\/AJR.10.4664","article-title":"Abdominal ultrasound with scintigraphic and clinical correlates in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"196","author":"McCarville","year":"2011","journal-title":"AJR. American Journal of Roentgenology"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0014|cit14","unstructured":"McCarville MB Rees RC Rogers ZR Kalpatthi R Miller ST Wang WC Adbominal ultrasound findings in infants with sickle cell anemia; baseline data from the BABY HUG Trial 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20 2009"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0015|cit15","unstructured":"McGann PT Flanagan JM Howard TA Dertinger SD He J Kulharya AS Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from BABY-HUG phase III clinical trial 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California 2011"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.23365","article-title":"Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial","volume":"59","author":"McGann","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0017|cit17","unstructured":"Miller ST Barredo J Brown C Bonds DR Casella JF Li D Renal concentrating ability in infants with sickle cell anemia; baseline data from Baby Hug, a multicenter trial 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA 2006"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/pbc.23244","article-title":"Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia","volume":"59","author":"Miller","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/pbc.22189","article-title":"Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG)","volume":"54","author":"Miller","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Miller ST Wang WC Iyer RV Rana SR Lane PA Ware RE Urine concentrating ability in infants with sickle cell anemia: baseline data from the Baby HUG trial Blood 2008","DOI":"10.1182\/blood.V112.11.1413.1413"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Miller ST Ware RE Kutlar A Alvarez OA Iyer RV Sarnaik SA Serum cystatin-C levels in infants with sickle cell anemia: baseline data from the BABY HUG trial Blood 2008","DOI":"10.1182\/blood.V112.11.4791.4791"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/pbc.22282","article-title":"Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"54","author":"Pavlakis","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"issue":"3","key":"10.1002\/14651858.CD012380.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"465-472, Supple","DOI":"10.1542\/peds.2014-0917","article-title":"Hydroxyurea and growth in young children with sickle cell disease","volume":"134","author":"Rana","year":"2014","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD012380.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1542\/peds.2014-0917","article-title":"Hydroxyurea and growth in young children with sickle cell disease","volume":"134","author":"Rana","year":"2014","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0025|cit25","unstructured":"Rogers ZR Capparelli EV Thompson B Ware RE Wang WC Iyer RV Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the Baby Hug trial 29th Annual Meeting of the National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA 2006 157"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Rogers ZR Rees RC Files B Iyer RV Shulkin BL Shalaby-Rana E Spleen function in infants with sickle cell anemia : baseline data from the BABY HUG trial Blood 2008","DOI":"10.1182\/blood.V112.11.1416.1416"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0027|cit27","unstructured":"Rogers ZR Rees RC Files B Iyer RV Shulkin BL Shalaby-Rana E Spleen function in infants with sickle cell anemia: baseline data from the Baby Hug trial 3rd Annual Sickle Cell Disease Research and Educational Symposium and Annual Sickle Cell Disease Scientific Meeting; 2009 Feb 18-20 2009"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0028|cit28","unstructured":"Rogers ZR Rees RR Wang WC Li D Iyer RV Rana S Evaluation of splenic function in infants with sickle cell anemia in the Baby Hug trial 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio 2005 106"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Rogers ZR Thompson B Ware RE Wang WC Iyer RV Miller ST Pharmacokinetics of hydroxyurea in young children with sickle cell anemia: a report from the BABY HUG trial Blood 2005","DOI":"10.1182\/blood.V106.11.3184.3184"},{"issue":"7","key":"10.1002\/14651858.CD012380.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.23457","article-title":"Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes","volume":"88","author":"Sheehan","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/pbc.22269","article-title":"The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design","volume":"54","author":"Thompson","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0032|cit32","unstructured":"Thompson BW Wang WC Miller ST Rogers ZR Ware RE Thornburg CD The physiological and clinical effects of interrupting a treatment regimen of hydroxyurea in young children with sickle cell anemia (SCA) 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California 2011"},{"issue":"22","key":"10.1002\/14651858.CD012380.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"4304-10; quiz 4","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pbc.22324","article-title":"Adherence to study medication and visits: data from the BABY HUG trial","volume":"54","author":"Thornburg","year":"2010","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Thornburg CD Rogers ZR Wang W Jeng M Rana SR Iyer RV Study drug and visit adherence: data from the Baby HUG trial Blood 2008","DOI":"10.1002\/pbc.22324"},{"issue":"7","key":"10.1002\/14651858.CD012380.pub2-BIB0036|cit36","first-page":"E20","article-title":"Effects of hydroxyurea in asymptomatic infants with sickle cell anemia: Analysis F from the BABY HUG trial","volume":"87","author":"Wang","year":"2012","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Wang W Rees RC Miller ST Brown RC Casella JF Iyer RV Transcranial doppler (TCD) ultrasonography in infants with sickle cell anemia: baseline data from the BABY HUG trial Blood 2008","DOI":"10.1182\/blood.V112.11.1436.1436"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1542\/peds.2013-0333","article-title":"Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia","volume":"132","author":"Wang","year":"2013","journal-title":"Pediatrics"},{"issue":"9778","key":"10.1002\/14651858.CD012380.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0040|cit40","unstructured":"Wang WC Yeku SO Luo Z Boulet SL Miller ST Fish B Costs associated with the care of very young children with sickle cell anemia (SCA): analysis from the BABY HUG study 53rd ASH Annual Meeting and Exposition; 2011 Dec 10-13; San Diego, California 2011"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Ware RE Rees RC Sarnaik SA Iyer RV Alvarez OA Casella JF Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial Blood 2008","DOI":"10.1182\/blood.V112.11.1414.1414"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpeds.2009.06.060","article-title":"Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial","volume":"156","author":"Ware","year":"2010","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0043|cit43","unstructured":"Wynn L Debenham E Faughnan L Martin B Kelly T Reed C Recruitment in the baby hug pediatric hydroxyurea phase 3 clinical trial 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington Dc, USA 2007 245"},{"issue":"6","key":"10.1002\/14651858.CD012380.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cct.2010.08.007","article-title":"Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study","volume":"31","author":"Wynn","year":"2010","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Wynn LW Faughnan L Li D Wang W Martin B Kelly T Recruitment of infants with sickle cell anemia to a phase III trials: data from the BABY HUG study Blood 2008","DOI":"10.1182\/blood.V112.11.1429.1429"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(98)00056-4","article-title":"A randomized trial of captopril for microalbuminuria in normotensive adults with sickle cell anemia","volume":"104","author":"Foucan","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3109\/03630269.2012.697948","article-title":"Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease","volume":"36","author":"Jain","year":"2012","journal-title":"Hemoglobin"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0048|cit48","unstructured":"NCT02373241 Preventing sickle cell kidney disease clinicaltrials.gov\/ct2\/show\/NCT02373241"},{"issue":"13","key":"10.1002\/14651858.CD012380.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and Morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0050|cit50","unstructured":"NCT01732718 Effect of atorvastatin on endothelial dysfunction and albuminuria in sickle cell disease (ENDO) clinicaltrials.gov\/ct2\/show\/NCT01732718"},{"issue":"10","key":"10.1002\/14651858.CD012380.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.amjmed.2008.04.040","article-title":"Surgical and obstetric outcomes in adults with sickle cell disease","volume":"121","author":"Adam","year":"2008","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"118","author":"Akinsheye","year":"2011","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pbc.20645","article-title":"Early blood transfusions protect against microalbuminuria in children with sickle cell disease","volume":"47","author":"Alvarez","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.24100","article-title":"Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia","volume":"59","author":"Alvarez","year":"2012","journal-title":"Pediatric Blood & Cancer"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2369-13-83","article-title":"Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: a prospective observational cohort study","volume":"13","author":"Arlet","year":"2012","journal-title":"BMC Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD012380.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"e69922","DOI":"10.1371\/journal.pone.0069922","article-title":"Determining glomerular filtration rate in Homozygous sickle cell disease: Utility of serum creatinine based estimating equations","volume":"8","author":"Asnani","year":"2013","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1002\/14651858.CD012380.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1179\/1607845414Y.0000000213","article-title":"Renal function in adult Jamaicans with homozygous sickle cell disease","volume":"20","author":"Asnani","year":"2015","journal-title":"Hematology"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Astor BC Matsushita K Gansevoort RT van der Velde M Woodward M Levey AS Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts Kidney International 2011 1331 40","DOI":"10.1038\/ki.2010.550"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ajh.23762","article-title":"The glomerulopathy of sickle cell disease","volume":"89","author":"Ataga","year":"2014","journal-title":"American Journal of Hematology"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ajh.23365","article-title":"Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia","volume":"88","author":"Aygun","year":"2013","journal-title":"American Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD012380.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2215\/CJN.05371008","article-title":"Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance","volume":"4","author":"Botev","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/sdi.12403","article-title":"Management of the dialysis patient with sickle cell disease","volume":"29","author":"Boyle","year":"2016","journal-title":"Seminars in Dialysis"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/sj.tpj.6500176","article-title":"Hydroxyurea down regulates endothelin-1 gene expression and up regulates ICAM-1 gene expression in cultured human endothelial cells","volume":"3","author":"Brun","year":"2003","journal-title":"Pharmacogenomics Journal"},{"issue":"20","key":"10.1002\/14651858.CD012380.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/asheducation-2013.1.439","article-title":"Transfusion therapy for sickle cell disease: a balancing act","volume":"2013","author":"Chou","year":"2013","journal-title":"Hematology \/ the Education Program of the American Society of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012380.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2013-03-490623","article-title":"High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors","volume":"122","author":"Chou","year":"2013","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0067|cit67","unstructured":"Veritas Health Innovation Covidence systematic review software 2015"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1523-1755.2004.09201.x","article-title":"Albuminuria, not only a cardiovascular\/renal risk marker, but also a target for treatment?","volume":"92","author":"Zeeuw","year":"2004","journal-title":"Kidney International. Supplement"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0069|cit69","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.2119\/molmed.2014.00187","article-title":"Advances in sickle cell therapies in the hydroxyurea era","volume":"20 Suppl 1","author":"Field","year":"2014","journal-title":"Molecular Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1172\/JCI30920","article-title":"Sickle cell disease: old discoveries, new concepts, and future promise","volume":"117","author":"Frenette","year":"2007","journal-title":"Journal of Clinical Investigation"},{"issue":"11","key":"10.1002\/14651858.CD012380.pub2-BIB0072|cit72","first-page":"1963","article-title":"Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials","volume":"10","author":"Gansevoort","year":"1995","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.ajkd.2005.10.014","article-title":"Timed urine collections are not needed to measure urine protein excretion in clinical practice","volume":"47","author":"Gaspari","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD012380.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/01.JIM.0000446836.75352.72","article-title":"Prevalence and progression of chronic kidney disease in adult patients with sickle cell disease","volume":"62","author":"Gosmanova","year":"2014","journal-title":"Journal of Investigative Medicine"},{"issue":"7526","key":"10.1002\/14651858.CD012380.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/515S1a","article-title":"Sickle-cell disease","volume":"515","author":"Gravitz","year":"2014","journal-title":"Nature"},{"issue":"6 Suppl 4","key":"10.1002\/14651858.CD012380.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa. A neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"American Journal of Preventive Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012380.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/pbc.24557","article-title":"Sickle cell disease related mortality in the United States (1999-2009)","volume":"60","author":"Hamideh","year":"2013","journal-title":"Blood Cancer"},{"issue":"5","key":"10.1002\/14651858.CD012380.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2215\/CJN.08511109","article-title":"Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature","volume":"5","author":"Haymann","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.hoc.2013.11.005","article-title":"Ischemia-reperfusion injury in sickle cell anemia: relationship to acute chest syndrome, endothelial dysfunction, arterial vasculopathy, and inflammatory pain","volume":"28","author":"Hebbel","year":"2014","journal-title":"Hematology\/oncology clinics of North America"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0080|cit80","unstructured":"Higgins JPT Deeks JJ editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0081|cit81","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0082|cit82","unstructured":"Higgins JPT Deeks JJ Altman DG editor(s) on behalf of the Cochrane Statistical Methods Group Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2141.2000.02040.x","article-title":"Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin","volume":"109","author":"Hillery","year":"2000","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.13348","article-title":"Guideline on the management of acute chest syndrome in sickle cell disease","volume":"169","author":"Howard","year":"2015","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.1002\/14651858.CD012380.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.20642","article-title":"Cerebrovascular disease associated with sickle cell pulmonary hypertension","volume":"81","author":"Kato","year":"2006","journal-title":"American Journal of Hematology"},{"issue":"6","key":"10.1002\/14651858.CD012380.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/blood-2005-06-2373","article-title":"Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease","volume":"107","author":"Kato","year":"2006","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0087|cit87","unstructured":"National Kidney Foundation KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease Kidney International Supplements 2013 1 163"},{"issue":"5","key":"10.1002\/14651858.CD012380.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ajh.21994","article-title":"Protective role of hemoglobin and fetal hemoglobin in early kidney disease for children with sickle cell anemia","volume":"86","author":"Lebensburger","year":"2011","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0089|cit89","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"11","key":"10.1002\/14651858.CD012380.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1681\/ASN.V10112426","article-title":"Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group","volume":"10","author":"Levey","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD012380.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"20","key":"10.1002\/14651858.CD012380.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2353\/ajpath.2006.050701","article-title":"Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular tTarget for renoprotective iIntervention","volume":"168","author":"Macconi","year":"2006","journal-title":"American Journal of Pathology"},{"issue":"10","key":"10.1002\/14651858.CD012380.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archinte.1995.00430100105012","article-title":"Long-term effects of antihypertensive agents on proteinuria and renal function","volume":"155","author":"Maki","year":"1995","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/ndt\/gfm858","article-title":"Proteinuria in children with sickle cell disease","volume":"23","author":"Marsenic","year":"2008","journal-title":"Nephrology, Dialysis, Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD012380.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/MPH.0b013e3180335081","article-title":"Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease","volume":"29","author":"McKie","year":"2007","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-Analyses:The PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD012380.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.ki.5000234","article-title":"Sickle cell disease, nephrotic syndrome, and renal failure","volume":"69","author":"Nasr","year":"2006","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD012380.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms","volume":"11","author":"Nath","year":"2015","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0100|cit100","unstructured":"National Institute for Health and Care Excellence Clinical knowledge summaries: Sickle cell disease cks.nice.org.uk\/sickle-cell-disease#!backgroundsub:3"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"614610","DOI":"10.1155\/2013\/614610","article-title":"Outcome and challenges of kidney transplant in patients with sickle cell disease","volume":"2013","author":"Okafor","year":"2013","journal-title":"Journal of Transplantation"},{"issue":"24","key":"10.1002\/14651858.CD012380.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"9861","key":"10.1002\/14651858.CD012380.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2012","journal-title":"Lancet"},{"issue":"7526","key":"10.1002\/14651858.CD012380.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/515S2a","article-title":"Epidemiology: a moving target","volume":"515","author":"Pleasants","year":"2014","journal-title":"Nature"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1182\/asheducation-2013.1.447","article-title":"Consequences and management of iron overload in sickle cell disease","volume":"1","author":"Porter","year":"2013","journal-title":"ASH Education Program Book"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"L314","DOI":"10.1152\/ajplung.00252.2014","article-title":"Vasculopathy and pulmonary hypertension in sickle cell disease","volume":"308","author":"Potoka","year":"2015","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"issue":"6","key":"10.1002\/14651858.CD012380.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012380.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1586\/17474086.2015.1078235","article-title":"A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease","volume":"8","author":"Pule","year":"2015","journal-title":"Expert Review of Hematology"},{"issue":"9757","key":"10.1002\/14651858.CD012380.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0110|cit110","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"e100516","DOI":"10.1371\/journal.pone.0100516","article-title":"The co-inheritance of alpha-thalassemia and sickle cell anemia Is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival","volume":"9","author":"Rumaney","year":"2014","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1002\/14651858.CD012380.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/03630269.2015.1040493","article-title":"Aging in sickle cell disease: co-morbidities and new issues in management","volume":"39","author":"Sandhu","year":"2015","journal-title":"Hemoglobin"},{"issue":"6","key":"10.1002\/14651858.CD012380.pub2-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009191.pub3","article-title":"Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease","author":"Sasongko","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012380.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MAJ.0b013e3181c70e14","article-title":"Delayed hemolytic transfusion reaction in sickle cell disease","volume":"339","author":"Scheunemann","year":"2010","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0115|cit115","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group Chapter 11: Presenting results and \u2018Summary of findings\u2019 tables. In: Higgins JPT, Green S, editor(s). Cochrane handbook for systematic reviews of interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0116|cit116","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P et al. on behalf of the Cochrane Applicability and Recommendations Methods Group Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0117|cit117","unstructured":"Sealed Envelope Ltd Power calculator for binary outcome superiority trial Available from: https:\/\/www.sealedenvelope.com\/power\/binary-superiority 2012"},{"issue":"24","key":"10.1002\/14651858.CD012380.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2014-02-557439","article-title":"How I treat renal complications in sickle cell disease","volume":"123","author":"Sharpe","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12336","article-title":"Interplay between coagulation and vascular inflammation in sickle cell disease","volume":"162","author":"Sparkenbaugh","year":"2013","journal-title":"British Journal of Haematology"},{"issue":"8","key":"10.1002\/14651858.CD012380.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/ajh.23232","article-title":"Genetic modifiers of sickle cell disease","volume":"87","author":"Steinberg","year":"2012","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0121|cit121","unstructured":"Sterne JAC Egger M Moher D editor(s) on behalf of the Cochrane Bias Methods Group Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"7","key":"10.1002\/14651858.CD012380.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood.V89.7.2554","article-title":"Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea","volume":"89","author":"Styles","year":"1997","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"2","key":"10.1002\/14651858.CD012380.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2141-9248.105655","article-title":"Prevalence of human immunodeficiency virus transmission among transfused children with sickle cell anemia in Enugu Nigeria","volume":"2","author":"Ubesie","year":"2012","journal-title":"Annals of Medical and Health Sciences Research"},{"key":"10.1002\/14651858.CD012380.pub2-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1755-1536-3-7","article-title":"The role of renin angiotensin system inhibition in kidney repair","volume":"3","author":"Meer","year":"2010","journal-title":"Fibrogenesis & Tissue Repair"},{"issue":"8","key":"10.1002\/14651858.CD012380.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0002-9149(85)90739-8","article-title":"Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension","volume":"55","author":"Ventura","year":"1985","journal-title":"American Journal of Cardiology"},{"issue":"9778","key":"10.1002\/14651858.CD012380.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD012380.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD012380.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2011-11-327361","article-title":"Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management","volume":"120","author":"Yazdanbakhsh","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD012380.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2215\/CJN.01600211","article-title":"Chronic kidney disease and albuminuria in children with sickle cell disease","volume":"6","author":"McPherson Yee","year":"2011","journal-title":"Clinical Journal of The American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD012380.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1053\/j.ajkd.2015.06.019","article-title":"Microcirculation in acute and chronic kidney diseases","volume":"66","author":"Zafrani","year":"2015","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD012380.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/157339908783502370","article-title":"Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy","volume":"4","author":"Ziyadeh","year":"2008","journal-title":"Current Diabetes Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd012380.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012380.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T02:02:26Z","timestamp":1719280946000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012380.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,7,3]]},"references-count":132,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012380.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727772189.793534659","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,3]]}}}